PBAC's latest decision on Atogepant: Recommended with restriction (2023). Considered for Prophylaxis of chronic migraine and high-frequency episodic migraine in adults who have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic migraine medications.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Adults with chronic migraine or high-frequency episodic migraine (≥8 migraine days per month over ≥6 months) who have experienced an inadequate response, intolerance or contraindication to at least three prophylactic migraine medications.
Therapy area
Neurology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Reduction in monthly migraine headache days; ≥50% reduction in monthly migraine headache days